Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination dietary supplement containing **Salacia chinensis extract**, **citrus bioflavonoids**, and **trivalent chromium** (often referenced as SEC) is clinically investigated for improvement of glucose control and metabolic health. **Salacia chinensis** includes polyphenolic compounds (salacinol, mangiferin, kotalanol) that inhibit *pancreatic lipase*, *aldose reductase*, and *alpha-glucosidase*, enzymes crucial for breaking down lipids and carbohydrates—thus reducing glucose absorption and fat digestion. **Citrus bioflavonoids** act as antioxidant and anti-inflammatory agents, potentially supporting glycemic and metabolic outcomes. **Trivalent chromium** is an essential micronutrient that enhances insulin receptor function, potentially aiding glucose uptake and insulin sensitivity. Clinical data show this triple combination reduces sweet cravings, glucose and insulin responses after an oral sucrose load, improves adiponectin, and may support kidney function. Primary indications are metabolic syndrome, glucose intolerance, obesity, and insulin resistance[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salacia extract + citrus bioflavonoids + trivalent chromium.